This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909–918.
Belperio JA, Keane MP, Arenberg DA et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1–8.
Brugarolas JB, Vazquez F, Reddy A et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147–158.
Dayanir V, Meyer RD, Lashkari K et al. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 2001;276:17686–17692.
Dimmeler S, Fleming I, Fisslthaler B et al. Activation of nitric oxide synthase in endothelial cells by AKT-dependent phosphorylation. Nature 1999;399:601–605.
Duda SH, Pusich B, Richter G et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505–1509.
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–4380.
Epstein AC, Gleadle JM, McNeill LA et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43–54.
Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005;23:S648 (abstract 4510).
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
Fulton D, Gratton JP, McCabe TJ et al. Regulation of endothelium-derived nitric oxide production by the protein kinase AKT. Nature 1999;399:597–601.
Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3^′-kinase/AKT signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336–30343.
Gnarra JR, Glenn GM, Latif F et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 1993;20:207–216.
Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85–90.
Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128–135.
Hainsworth JD, Sosman JA, Spigel DR et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). J Clin Oncol 2004;22:14S (abstract 4502).
Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47.
Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700–9704.
Ivan M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001;11:27–34.
Ivan M, Kondo K, Yang H et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464–468.
Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468–472.
Jiang BH, Jiang G, Zheng JZ et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:363–369.
Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673–682.
Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117–125.
Kondo K, Klco J, Nakamura E et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237–246.
Lam JS, Leppert JT, Yu H et al. Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma. J Clin Oncol 2005;23:16S (abstract 4538).
Laughner E, Taghavi P, Chiles K et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995–4004.
Leppert JT, Lam JS, Yu H, et al. Targeting the vascular endothelial growth factor pathway in renal cell carcinoma, a tissue array based analysis. J Clin Oncol 2005:23:16S (abstract 4536).
Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436–445.
Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219–225.
Maranchie JK, Vasselli JR, Riss J et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247–255.
Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271–275.
Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–337.
Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–1780.
Motzer RJ, Rini BI, Michaelson MD et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 2005;23:16S (abstract 4508).
Mullins IM, Slingluff CL, Lee JK et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64:7697–7701.
Pantuck AJ, Zeng G, Belldegrun AS et al. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641–4652.
Ratain MJ, Eisen T, Stadler WM et al. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) J Clin Oncol 2005;23:16S (abstract 4544).
Ratain MJ, Flaherty KT, Stadler WM et al. Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 2004;22:14S (abstract 4501).
Reckamp KL, Burdick MD, Strieter RM et al. The importance of the CXCR3/CXCR3 ligand biological axis in metastatic renal cell carcinoma. Proc Am Assoc Cancer Res 2005;46:1092 (abstract 4627).
Rini B, Rixe O, Bukowski R et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005;23;16S (abstract 4509).
Risau W. Mechanisms of angiogenesis. Nature 1997;386: 671–674.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–732.
Spigel DR, Hainsworth JD, Sosman A et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a phase II multicenter trial. J Clin Oncol 2005;23;16S (abstract 4540).
Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2001;2:285–286.
Strieter RM, Belperio JA, Arenberg DA et al. CXC chemokine in angiogenesis. In: Universes in Delicate Balance: Chemokines and the Nervous System. R.M. Ransohoff, K. Suzuki, A.E.I. Proudfoot, and W.F. Hickey, Eds. Elsevier Science B.V., Amsterdam, The Netherlands, 2002, p. 129.
Strieter RM, Polverini PJ, Kunkel SL et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348–27357.
Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434.
Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999;178:235–246.
Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60: 1541–1545.
Zundel W, Schindler C, Haas-Kogan D et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391–396.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Reckamp, K.L., Strieter, R.M., Figlin, R.A. (2008). Antiangiogenic Therapies in Renal Cell Carcinoma. In: Rosette, J.J.d., Sternberg, C.N., Poppel, H.P.v. (eds) Renal Cell Cancer. Springer, London. https://doi.org/10.1007/978-1-84628-763-3_47
Download citation
DOI: https://doi.org/10.1007/978-1-84628-763-3_47
Publisher Name: Springer, London
Print ISBN: 978-1-84628-385-7
Online ISBN: 978-1-84628-763-3
eBook Packages: MedicineMedicine (R0)